Last
Update:
March 10, 2012
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
Pediatric data are indexed in the
pediatric section
19th Conference on Retroviruses and
Opportunistic
Infections |
-
POSTER
Safety, Efficacy, and Pharmacokinetic of Darunavir/ritonavir-containing
Regimen in Pregnant HIV+ Women
E Courbon, S Matheron, L
Mandelbrot, et al
PDF Poster
Abstract
-
POSTER
Total and Unbound Darunavir
Pharmacokinetics in HIV-1+ Pregnant Women
C Zorrilla, R Wright, O
Osiyemi, et al
PDF Poster
Abstract
-
POSTER
A Comparison of the Pharmacokinetics of Darunavir, Atazanavir, and Ritonavir
during Pregnancy and Post-partum
A Colbers, J Molto, J
Ivanovic, et al
PDF Poster
Abstract
-
POSTER
Low Darunavir and Etravirine Exposure When Used in Combination in HIV+
Children and Adolescents
J King, R Yogev, A Wiznia, et al
PDF Poster
Abstract
-
POSTER
Pharmacokinetic Interaction between the HCV Protease Inhibitor Boceprevir and
Ritonavir-boosted HIV-1 Protease Inhibitors Atazanavir, Lopinavir, and Darunavir
E Hulskotte, H-P Feng, F
Xuan, et al
PDF Poster
Abstract
-
POSTER
Darunavir/ritonavir Does Not
Significantly Increase Plasma Concentrations of Orally Inhaled Beclomethasone
in Healthy Volunteers
S Boyd, C Hadigan, A Pau,
et al
PDF Poster
Abstract
-
POSTER
Unique Flap Conformation of
Darunavir-resistant HIV-1 Protease
K Suzuki, H Ode, M Fujino, et al
PDF Poster
Abstract
-
POSTER
Association between Markers of
Immune Activation, Inflammation, Coagulation, and Virologic Failure in ACTG
A5262:
A Single-arm Study of Darunavir/ritonavir Plus Raltegravir in Treatment-naïve
HIV-1+ Patients
C Wilson, R Matining, J Eron, et al
PDF Poster
Abstract
-
POSTER
Bayesian Network Analysis of
Mutational Pathways to Darunavir Resistance
G Beheydt, K Theys, B
Clotet, et al
PDF Poster
Abstract
-
Simultaneous Pharmacogenetics-based Population Pharmacokinetic Analysis of
Darunavir and Ritonavir in HIV+ Individuals
J Molto, M Valle, G
Xinarianos, et al
Abstract
|
-
POSTER
Study of the immunomodulant effect of
darunavir and maraviroc on apoptosis of PBMC
I. Sauzullo, F. Mengoni, A. Ermocida, et al
Poster
Abstract
- POSTER
Persistence of antiretroviral regimens including raltegravir, maraviroc,
darunavir and/or etravirine in clinical practice
I. Castillo Romera, N. Trovato López, S. Plata Paniagua, et al
Poster
Abstract
- POSTER
A n approach to the management of children failing second-line
antiretroviral therapy (ART) at the Botswana-Baylor
Children's Clinical Centre of Excellence (COE) and decentralized ART sites in
Botswana
M. Tolle, A. Gomila, H. Jibril, et al
Poster
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
The MONET trial: week
144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r +
2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline
J. Arribas, N. Clumeck, M. Nelson, et al
Abstract
-
Long-term safety of
once-daily (QD) darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r)
in HIV-1-infected treatment-naïve patients in ARTEMIS
N. Clumeck, B.J. Barnett, P. Ive, et al
Abstract
-
A comparative analysis
of risk factors associated with efavirenz, darunavir/ritonavir,
lopinavir/ritonavir, atazanavir/ritonavir and renal impairment
N. Rockwood, M. Nelson, S. Mandalia, B. Gazzard
Abstract
-
24-week efficacy,
safety, tolerability, and pharmacokinetics (PK) of darunavir/ritonavir (DRV/r)
once daily (qd) in
treatment-naive
adolescents aged 12 to < 18 years in DIONE
P. Flynn, S. Blanche, C. Giaquinto, et al
Abstract
-
Virological impact of
introducing darunavir and raltegravir for multiexperienced HIV-1-infected
patients in Brazil
R. Hallal, H. Bernal, R. Kuchenbecker, et al
Abstract
-
Frequency of
resistance associated mutations to the third line protease inhibitors in
Mexican heavily antiretroviral-treated patients: report of a national advisory
board (CORESAR)
J. Andrade Villanueva, J.G. Sierra-Madero, J. Casillas Rodríguez, et al
Abstract
-
Despite different
instantaneous inhibitory potentials, boosted-atazanavir and boosted-darunavir
had similar clinical outcomes
G. Simoncini, C. Chien, J.C. Ricaurte, et al
Abstract
-
Dual therapy with
darunavir/ritonavir and etravirine in clinical practice: an NRTI-sparing
strategy in ART experienced patients
J.I. Bernardino, J. Vergas, M.J. Tellez, et al
Abstract
-
NRTI-sparing regimen
in clinical practice: the SCOLTA cohort
A. Di Biagio, P. Maggi, G. Pellicanò, et al
Abstract
-
Response to salvage
therapy among heavily ART experienced individuals at the Joint Clinical
Research Centre (JCRC) Kampala, Uganda
F. Ssali, J. Akao, J. Nantiba, et al
Abstract
18th Conference on Retroviruses and
Opportunistic
Infections |
Pharmacokinetics of DRV/r in
Asian HIV-1+ 6-Year-old Children
K Chokephaibulkit, W
Prasitsuebsai, O Wittawatmongkol, et al
PDF Poster
Abstract
POSTER
Randomized Comparison of DRV/r vs ATV/r on Serum
Lipids in HIV+ Persons on Fully Suppressive LPV/r or FPV/r
with High Serum Triglycerides
D Skiest, C Cohen, H
Khanlou, et al
PDF Poster
Abstract
POSTER
Intracellular Pharmacokinetics
and Drug Interaction between DRV/r Once Daily and RAL Once and Twice Daily
in
HIV-infected Individuals
A Jackson, D Back, S
Khoo, et al
PDF Poster
Abstract
A WEEK-IN-REVIEW FEATURED
REPORT
POSTER
Results from a Single Arm Study
of DRV/r + RAL in Treatment-naïve HIV-1-infected Patients (ACTG A5262)
B Taiwo, S Zheng, S
Gallien, et al
PDF Poster
Abstract
POSTER
Genetic Barrier of DRV Is
Decreased by gag Polymorphisms
A Fun, D de Jong,
M Nijhuis
PDF Poster
Abstract
POSTER
Pharmacokinetics of DRV/r and
ATV/r Once Daily over 72 Hours following Drug Cessation
M Boffito, A Jackson, A
Amara
PDF Poster
Abstract
POSTER
Therapeutic DRV and ETR
Concentrations in Cerebrospinal Fluid
B Best, S Letendre, D
Croteau, et al
PDF Poster
Abstract
Positive Impact of HIV-1 gag CS A431V Mutation on
Virologic Response to DRV/r Boosted with Ritonavir
L Larrouy S Lambert-Niclot
C Charpentier, et al
Abstract
ARV for
HIV Prevention: DRV + Low-dose RTV and ETR Exposure in the Rectal Tissue and
Seminal Plasma of
Healthy
Male Volunteers after Single and Multiple Dosing
K Brown, K Patterson, S
Jennings, et al
Abstract
XVIII International AIDS Conference
|
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of
two BOosted
protease inhibitors on LIpids and other marKers): comparison of the metabolic
effects of
darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks
J. Aberg, T. Overton, S. Gupta, et al
PDF Poster
Abstract
POSTER
Drug-resistant genotyping to guide selection of etravirine, darunavir and
raltegravir in salvage
therapy for multi-drug-resistant cases improves outcomes
N. Miyazaki1, S. Matsushita, T. Fujii, et al
PDF Poster
Abstract
POSTER
Duration of antiretroviral regimens including Raltegravir, Maraviroc,
Darunavir and/or Etravirine in
clinical practice
I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al
PDF Poster
Abstract
Comparison of liver
toxicity in HIV/HCV coinfected and HIV monoinfected patients during 72 weeks
ART including darunavir/ritonavir
G. Morsica, G. Bianchi, S. Bagaglio, et al
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
The MONET trial 96
week analysis: darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for
patients with HIV
RNA < 50 copies/mL at baseline
A. Rieger, D. Banhegyi, W. Schmidt, et al
Abstract
Hepatic safety of
darunavir 600/100 in HCV coinfected patients with HAART experience
M.A. von Wichmann, M. Saenz-Cuesta, K. Aguirrebengoa, et al
Abstract
Effects of
once-daily (qd) versus twice-daily (bid) darunavir/ritonavir (DRV/r) on lipid
parameters
at week 48 in treatment-experienced, HIV-1-infected patients with no DRV
resistance-associated
mutations (RAMs) in the ODIN study
J. Arribas, E. Arathoon, C.R. Gonsalez, et al
Abstract
Darunavir/ritonavir
(DRV/rtv) increases rosuvastatin (RSV) concentrations but does not alter
lipid-lowering
effect in healthy volunteers
C. Fichtenbaum, D. Samineni, E. Moore, et al
Abstract
Hard rescue:
prospective study of effectiveness and safety of new drugs (Darunavir-DRV,
Etravirina-ETR,
Raltegravir-RTG and Maraviroc-MVC) in the last four years (2006-2009)
H. Azkune Galparsoro, J.A. Iribarren Loyarte, M.J. Aramburu Bengoechea
Abstract
Effect of adherence
on virological response to once-daily (qd) versus twice-daily (bid)
darunavir/ritonavir (DRV/r) in treatment-experienced, HIV-1-infected patients
with no DRV
resistance-associated mutations (RAMs): ODIN 48-week data
C. Workman, P. Benson, J. Valdez Madruga, et al
Abstract
Genotypic
resistance to darunavir, tipranavir and etravirine in patients with failure to
two or more
ARV combinations in Mexico
E. Vidal-Laurencio, L. Cabrera-Ruiz, A. Flores-Gaxiola, et al
Abstract
Low prevalence of
darunavir resistance mutations among HIV-1-infected patients exposed to
second-line protease
inhibitors in South India
S. Saravanan, M. Vidya, R. Kantor, et al
Abstract
Subgroup analysis and predictors of virologic response in
treatment-experienced HIV-1-infected
patients in the ODIN trial
P. Cahn, S. Hodder, P. Mootsikapun, et al
Abstract
17th Conference on Retroviruses and
Opportunistic
Infections |
-
A WEEK-IN REVIEW FEATURED REPORT
POSTER
Fat Tissue Distribution Changes in
HIV-infected Patients with Viral Suppression Treated
with CDRV/r Monotherapy vs 2 NRTI + DRV/r in the MONOI–ANRS 136 Randomized
Trial: Results at 48 Weeks
M-A Valantin, P Flandre, S Kolta,
et al
PDF Poster
Abstract
POSTER
The Binary Protease Inhibitor, Darunavir, Has a High Genetic Barrier to the
Emergence of
Resistant HIV-1 Variants
Y Koh, M Aoki, M Amano, et
al
PDF Poster
Abstract
POSTER
Darunavir Concentrations in Seminal
Plasma in Patients Receiving Darunavir/Ritonavir
Monotherapy: A MONOI-ANRS 136 Substudy
S L-Niclot, C Duvivier, M Algarte-Genin,
et al
PDF Poster
Abstract
POSTER
Prevalence of Darunavir-associated
Mutations in PI-naive and PI-experienced HIV-1-infected
Children in the UK
K Boyd, S Walker, D Dunn, et al
PDF Poster
Abstract
POSTER
Darunavir Concentrations Exceed the
Protein-corrected EC50 for Wild Type HIV in the Semen
of HIV-1+ Men
S Taylor, A Jayasuriya, N Dufty, et al
PDF Poster
Abstract
POSTER
Ultradeep Sequencing Refines
Phenotypic Predictions to Darunavir, Etravirine, and Other Protease
and Reverse Transcriptase Inhibitors in Heavily Pre-treated Subjects Infected
with Multidrug
Resistant HIV-1
F Codoñer, C Pou, A Thielen,
et al
PDF Poster
Abstract
POSTER
Bulk and Clonal Resistance Analyses
in Highly Experienced Patients Failing Raltegravir-, Etravirine-, and
Darunavir/ritonavir-containing Regimen (ANRS 139 TRIO Trial)
B Roquebert, C Colin, A-M Taburet, et al
PDF Poster
Abstract
12th European AIDS
Conference
|
A WEEK-IN-REVIEW FEATURED REPORT
PRESENTATION
Non-inferior efficacy shown across different
efficacy endpoints in the MONET trial of darunavir/ritonavir
monotherapy
D Ripamonti, J Arribas,
M
Nelson, et al
PowerPoint Presentation
POSTER
Non-inferior efficacy shown across different
efficacy endpoints in the MONET trial of darunavir/ritonavir
monotherapy
D Ripamonti, J Arribas,
M Nelson, et al
PDF Poster
POSTER
Comparative regimen durability and discontinuation reasons
among 3-class experienced patients in
a US clinical cohort
JH. Willig, I Aban, CR. Nevin, et al
PDF Poster
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Analysis of drug resistance during HIV RNA viraemia in the
MONET trial of darunavir/ritonavir
monotherapy
M Nelson, J Arribas, F Pulido, et al
PDF Poster
POSTER
Cost-efficacy analysis of the MONET trial using German antiretroviral drug
prices
M Stoll, A Hill, A Anceau, C Moecklinghoff
PDF Poster
POSTER
Low-level HIV RNA viraemia in the MONET trial: effects of assay variability
and inter-current infection
A Hill, MC Pineiro, J Arribas, et al
PDF Poster
POSTER
Treatment-experienced Women and Men in
GRACE(Gender, Race And Clinical Experience)
K Squires, J Currier, J Mrus, et al
PDF Poster
POSTER
Pharmacokinetic and Pharmacodynamic Analyses of
Darunavir in Treatment-experienced Women and
Men in GRACE (Gender, Race And Clinical Experience)
V Sekar, P Vis, B Coate, et al
PDF Poster
PRESENTATION
A Phase II, open-label trial in treatment-naïve,
HIV-1-infected patients who received DRV/r as induction
monotherapy
P Patterson, A Krolewiecki, F Tomaka, et al
PowerPoint Presentation
POSTER
Comparison of gastrointestinal adverse events of
darunavir/ritonavir and lopinavir/ritonavir at Week 96 in
ARTEMIS
J Flamm, B Rodwick, P Ive, et al
PDF Poster
POSTER
ARTEMIS 96-week comparison of liver tolerability
of once-daily darunavir/ritonavir versus lopinavir/ritonavir
in treatment-naïve patients
G Fätkenheuer, M Kelly, E Van Wijngaerden, et al
PDF Poster
|
-
A WEEK-IN-REVIEW-FEATURED REPORT
CONFERENCE PDF POSTER
GRACE (Gender,
Race And Clinical Experience): 48-week results of
darunavir/r-based therapy in the largest trial in North America focused on
treatment-experienced women
K. Squires, J. Currier, D. Bridge, et al
-
CONFERENCE POSTER
ARTEMIS: week 96 safety and efficacy of darunavir/r by gender, age and race
J. Fourie, J. Flamm, A. Rodriguez-French, et al
PDF Poster
Abstract
-
CONFERENCE POSTER
Gender analysis of darunavir in combination with low-dose ritonavir (600/100 mg
bid): results at 4
8 weeks from 79 Italian centers participating to the Expanded Access Program (EAP)
TMC114-C226
R. Termini, A. Castagna, F. Gatti, et al
PDF Poster
Abstract
-
CONFERENCE POSTER
Prevalence of darunavir resistance mutations in multi-experienced HIV-1
infected patients failing
other protease inhibitors in a developing country with free access to highly
active antiretroviral
therapy and genotyping
J.E. Vidal, A.C. Freitas A.V. Hernandez
PDF Poster
Abstract
-
CONFERENCE POSTER
Genotypic, phenotypic and virtual phenotypic
resistance patterns for tipranavir (TPV)
and darunavir (DRV): an independent analysis of a Quebec HIV-1 cohort highly
resistant
to all other protease inhibitors
A. Talbot, P. Grant, J. Taylor,
et al
PDF Poster
Abstract
-
Efficacy of
darunavir/ritonavir as single-drug maintenance therapy in patients with
HIV-1 viral
suppression: a
randomized open-label non-inferiority trial, MONOI-ANRS 136
C. Katlama, M.A. Valentin, M. Algarte-Genin, et al
Abstract
-
Agreement
degree between two genotype interpretation systems, tipranavir (TPV) and
darunavir
(DRV) validated
weighted scores (WS) and Stanford HIVdb program
M.J. Pérez Elías, C. Gutierrez, J.L. Casado
Abstract
-
Effects of
once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid
parameters and
anthropometrics in treatment-naïve HIV-1-infected ARTEMIS patients at week
96
E. Baraldi, J. Morales-Ramírez, S. Schneider, et al
Abstract
-
Darunavir/ritonavir once daily: a single centre cohort experience
C. Scott, J. Dunning, A. Teague, et al
Abstract
-
The MONET trial:
darunavir/ritonavir monotherapy shows non-inferior efficacy to standard
HAART,
for patients with HIV RNA < 50 copies/mL at baseline
J. Arribas, A. Horban, J. Gerstoft, et al
Abstract
-
48-week lipid-
and glucose-related safety profile of darunavir/ritonavir in
treatment-experienced,
paediatric
patients in DELPHI
T. Meyers, E. Joao, J.H. Pilotto, et al
Abstract
-
Recovery of
functional immunity over 48 weeks with darunavir-based therapy in the GRACE
immunology substudy
C. Tsoukas, L. Gilbert, T. Lewis, et al
Abstract
|
XVII International AIDS Conference
|
|
Darunavir Main Page
Main
New/Newsworthy
